Abstract | BACKGROUND/AIMS: METHODOLOGY: Twenty-four patients were enrolled. 7 patients were considered to have inoperable tumors or rejected surgery after HCRT, and the remaining 17 patients had an esophagectomy. Clinical responses, HCRT toxicity and survival after surgery were evaluated. RESULTS: In the 24 patients, the response rate was 41.7%. The pathological complete response (pCR) rate was 17.6% in the 17 patients. HCRT toxicity grade 2 occurred in six patients (25.0%: esophagitis, 4; leukopenia, 6; neutropenia, 4) and grade 3 ( pneumonia) in 3 patients (12.5%). The 3- and 5-year survival rates were 56.3% and 50.0%, respectively. When the patients were divided into a pCR group and a pathological partial response (pPR) group, the 3-year survival rates were 66.7% and 42.9% and the 5-year survival rates were 66.7% and 42.9%, respectively (log-rank P = .5842). CONCLUSIONS:
|
Authors | Masanobu Nakajima, Hiroyuki Kato, Makoto Sakai, Akihiko Sano, Tatsuya Miyazaki, Makoto Sohda, Takanori Inose, Naritaka Tanaka, Shigemasa Suzuki, Norihiro Masuda, Minoru Fukuchi, Hiroyuki Kuwano |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
Vol. 62
Issue 140
Pg. 887-91
(Jun 2015)
ISSN: 0172-6390 [Print] Greece |
PMID | 26902022
(Publication Type: Clinical Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Taxoids
- Docetaxel
|
Topics |
- Aged
- Antineoplastic Agents
(administration & dosage)
- Carcinoma, Squamous Cell
(therapy)
- Chemoradiotherapy
(adverse effects, methods)
- Cohort Studies
- Docetaxel
- Esophageal Neoplasms
(therapy)
- Esophageal Squamous Cell Carcinoma
- Esophagectomy
- Esophagitis
(etiology)
- Female
- Humans
- Hyperthermia, Induced
(adverse effects, methods)
- Leukopenia
(etiology)
- Male
- Middle Aged
- Neoadjuvant Therapy
(adverse effects, methods)
- Neutropenia
(etiology)
- Prospective Studies
- Survival Rate
- Taxoids
(administration & dosage)
- Treatment Outcome
|